Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer.

Kambiz RahbarMartin BögemanAnna YordanovaMaria EveslageMichael SchäfersMarkus EsslerHojjat Ahmadzadehfar

Published in: European journal of nuclear medicine and molecular imaging (2017)

RLT with Lu-177-PSMA-617 shows respectable response rates. In this retrospective analysis, a relevant number of patients showed a delayed response, even if they did not respond to the first cycle of the therapy.

Keyphrases

pet ct
ejection fraction
newly diagnosed
pet imaging
prognostic factors
stem cells
computed tomography
bone marrow